ARGX 119
Alternative Names: ARGX-119Latest Information Update: 06 Jul 2025
At a glance
- Originator argenx; Leiden University Medical Center
- Developer argenx
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action MUSK protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
- Phase I Congenital myasthenic syndromes
Most Recent Events
- 30 Jun 2025 Adverse events andefficacy data from a phase-Ib trial in Congenital myasthenic syndromes released by Argenx
- 30 Jun 2025 Argenx plans a registrational trial for Congenital myasthenic syndromes (IV)
- 08 Apr 2025 Adverse events data from a phase I trial in Congenital myasthenic syndromes released by argenx